Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC5004 DDI study with statins, digoxin and midazolam
NCT06293742Phase 1Completed
- Sponsor
- Eccogene
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elecoglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Eccogene. Primary endpoints: Atorvastatin Area Under the Curve (0-tlast), Atorvastatin Area Under the Curve (0-inf) and 10 more. Started Feb 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06293742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293742.